| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | hepatitis B virus surface antigen |
| Clinical data | |
| Other names | GC1102 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lenvervimab ( INN; [1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B. [2]
This drug is being developed by GC Pharma. As of 2018 [update], lenvervimab is undergoing Phase II/ III trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- ^ Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8): e0236704. Bibcode: 2020PLoSO..1536704J. doi: 10.1371/journal.pone.0236704. PMC 7425877. PMID 32790777.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |